Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBT Margin (2019 - 2025)

Keros Therapeutics (KROS) has disclosed EBT Margin for 6 consecutive years, with 6572.37% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 1557355.0% year-over-year to 6572.37%, compared with a TTM value of 37.68% through Dec 2025, down 22532738.0%, and an annual FY2025 reading of 37.68%, changed N/A over the prior year.
  • EBT Margin was 6572.37% for Q4 2025 at Keros Therapeutics, down from 61.86% in the prior quarter.
  • Across five years, EBT Margin topped out at 1583500.0% in Q1 2021 and bottomed at 541000.0% in Q3 2023.
  • Average EBT Margin over 5 years is 61476.97%, with a median of 157.78% recorded in 2022.
  • The sharpest move saw EBT Margin plummeted -158363437bps in 2022, then skyrocketed 52735155bps in 2024.
  • Year by year, EBT Margin stood at 27.6% in 2021, then surged by 649bps to 151.48% in 2022, then crashed by -21546bps to 32486.01% in 2023, then surged by 128bps to 9001.18% in 2024, then plummeted by -173bps to 6572.37% in 2025.
  • Business Quant data shows EBT Margin for KROS at 6572.37% in Q4 2025, 61.86% in Q3 2025, and 181.19% in Q2 2025.